{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.3"},{"groupId":"OG001","value":"62.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"48"}],"units":"Participants"}],"description":"BM aspirate was collected for fluorescent in situ hybridization for analysis of del\\[17p\\], t\\[4;14\\], t\\[14;16\\]) and 1q21+. ORR was also evaluated based on IRC assessment by disease characteristics. ORR for participants with at least 1 chromosomal abnormality i.e. \\[del(17p)\\] or \\[1q21+ and t(4;14) or t(14;16)\\] is presented. Percentages are rounded off to the tenth decimal place.","groups":[{"description":"Participants received isatuximab 10 mg/kg IV infusion QW (i.e. on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 10 mg/kg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG000","title":"Isa-IV + Pd"},{"description":"Participants received isatuximab 1400 mg SC injection administered via an OBDS which is an investigational device injector QW (i.e on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 1400 mg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG001","title":"Isa-SC + Pd"}],"paramType":"NUMBER","populationDescription":"The ITT population included all randomized population. Only participants with at least 1 chromosomal abnormality are included in the analysis.","reportingStatus":"POSTED","timeFrame":"From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months","title":"ORR Based on at Least 1 Chromosomal Abnormality","type":"SECONDARY","unitOfMeasure":"percentage of participants"}